EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Harnessing transcription factor-driven ROS for synergistic multimodal lung cancer treatment

Ye Zhou, Simeng Wang, Jiahua Guo, Chenghao Li, Mengjun Sui, Zekun Zeng, Hui Dang, Qingqing Gu, Jian Zhu, Yangyang Cheng, Peng Hou

Journal of Controlled Release · 2024

DOI: 10.1016/j.jconrel.2024.08.035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Ye Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'…. Hauptthemen laut MEDLINE: Lung Neoplasms, Reactive Oxygen Species, Prodrugs, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Xi’an Jiaotong University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multimodal treatment of cancer is an unstoppable revolution in clinical application. However, designing a platform that integrates therapeutic modalities with different pharmacokinetic characteristics remains a great challenge. Herein, we designed a universal lipid nanoplatform equipping a ROS-cleavable docetaxel prodrug (DTX-L-DTX) and an NF-E2-related factor 2 (NRF2) inhibitor (clobetasol propionate, CP). This simply fabricated nanomedicine enables superior synergistic molecularly targeted/chemo/radio therapy for lung cancer cascade by a transcription factor-driven ROS self-sustainable motion. Chemotherapy is launched via ROS-triggered DTX release. Subsequently, CP inhibits the expression of NRF2 target genes, resulting in efficient targeted therapy, meanwhile inducing sustained ROS generation which in turn facilitates chemotherapy by overcoming ROS consumption during the DTX release process. Finally, the introduction of radiotherapy further amplifies ROS, offering continuous mutual feedback to amplify the ultimate treatment performance. This strategy is conceptually and operationally simple, providing solutions to challenges in clinical cancer treatment and beyond.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsReactive Oxygen SpeciesProdrugsAntineoplastic AgentsDocetaxelNF-E2-Related Factor 2HumansAnimalsNanoparticlesCombined Modality TherapyMice, NudeMice, Inbred BALB CCell Line, TumorA549 CellsDrug LiberationFemale

Stichwörter der Autor:innen

Drug deliveryMultimodal cancer therapyNRF2-targetedROS-responsiveSelf-sustainable strategy

Substanzen

Reactive Oxygen SpeciesProdrugsAntineoplastic AgentsDocetaxelNF-E2-Related Factor 2

Autor:innen und Institutionen

  • Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an 710061, PR China; Department of Endocrinology, The First Affiliated…
  • Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an 710061, PR China; National Engineering Research Center for Miniaturized Detection Systems, College of L…
  • Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710049, PR China. Electronic address: zhujian@mail.xjtu.edu.cn.

Förderung

  • Xi’an Jiaotong University
  • National Natural Science Foundation of China

Zitieren

APA

Zhou, Y., Wang, S., Guo, J., Li, C., Sui, M., Zeng, Z., Dang, H., Gu, Q., Zhu, J., Cheng, Y., & Hou, P. (2024). Harnessing transcription factor-driven ROS for synergistic multimodal lung cancer treatment. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.08.035

Vancouver

Zhou Y, Wang S, Guo J, Li C, Sui M, Zeng Z, et al. Harnessing transcription factor-driven ROS for synergistic multimodal lung cancer treatment. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.08.035

BibTeX
@article{Zhou2024,
  author = {Zhou, Ye and Wang, Simeng and Guo, Jiahua and Li, Chenghao and Sui, Mengjun and Zeng, Zekun and Dang, Hui and Gu, Qingqing and Zhu, Jian and Cheng, Yangyang and Hou, Peng},
  title = {Harnessing transcription factor-driven ROS for synergistic multimodal lung cancer treatment},
  journal = {Journal of Controlled Release},
  year = {2024},
  doi = {10.1016/j.jconrel.2024.08.035}
}
Kostenlos starten →